Literature DB >> 2183929

Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells.

J W Koper1, J A Foekens, R Braakman, S W Lamberts.   

Abstract

The presence of receptors for progesterone in a large proportion of human meningioma tissues is well established. The occurrence of increased rates of growth of meningiomas in situ during pregnancy suggests the existence of a relationship between high progesterone levels and the growth of meningiomas. However, experiments with cultured meningioma tissue (cells or explants) have shown only minimal effects of progesterone. It has been shown recently that many meningiomas have receptors for epidermal growth factor. In this paper we have investigated the response of cultured human meningioma cells to epidermal growth factor and other growth factors and the modulation of this response by progesterone and the progesterone-receptor blocking agent mifepristone (RU 38486). The results suggest that the presence of progesterone in the culture medium increases the sensitivity of meningioma cells to mitogenic stimuli, whereas mifepristone can counteract the stimulating effects of progesterone.

Entities:  

Keywords:  Biology; Data Analysis; Endocrine System; Examinations And Diagnoses; Histology; Hormone Receptors--analysis; Hormones; Incidence; Laboratory Examinations And Diagnoses; Measurement; Membrane Proteins; Physiology; Progestational Hormones; Progesterone--analysis; Research Methodology

Mesh:

Substances:

Year:  1990        PMID: 2183929

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Insulin-like growth factors in central nervous system tumors.

Authors:  R P Glick; T Lichtor; T G Unterman
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

2.  Expression of the c-erbB-2-encoded oncoprotein and progesterone receptor in human meningiomas.

Authors:  J Schlegel; B Ullrich; G Stumm; P Gass; I M Harwerth; N E Hynes; M Kiessling
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

3.  A t(4;22) in a meningioma points to the localization of a putative tumor-suppressor gene.

Authors:  R H Lekanne Deprez; N A Groen; N A van Biezen; A Hagemeijer; E van Drunen; J W Koper; C J Avezaat; D Bootsma; E C Zwarthoff
Journal:  Am J Hum Genet       Date:  1991-04       Impact factor: 11.025

4.  Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase.

Authors:  Mahlon D Johnson; Ann Woodard; Evelyn J Okediji; Steven A Toms; George S Allen
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

5.  Mifepristone (RU 486) treatment of meningiomas.

Authors:  S W Lamberts; H L Tanghe; C J Avezaat; R Braakman; R Wijngaarde; J W Koper; H de Jong
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-06       Impact factor: 10.154

6.  Expression of PDGF, PDGF-receptor, EGF-receptor and sex hormone receptors on meningioma.

Authors:  J I Kuratsu; H Seto; M Kochi; Y Ushio
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

7.  Involvement of protein kinase C in growth regulation of human meningioma cells.

Authors:  T Todo; R Fahlbusch
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  Traumatic origin of a meningioma?

Authors:  P Betz; W Eisenmenger
Journal:  Int J Legal Med       Date:  1995       Impact factor: 2.686

Review 9.  The Role of Mifepristone in Meningiomas Management: A Systematic Review of the Literature.

Authors:  Giulia Cossu; Marc Levivier; Roy Thomas Daniel; Mahmoud Messerer
Journal:  Biomed Res Int       Date:  2015-06-03       Impact factor: 3.411

10.  Regression of Giant Olfactory Groove Meningioma and Complete Visual Acuity Recovery after Discontinuation of Cyproterone Acetate.

Authors:  Anne Laure Bernat; Sophie Bonnin; Moujahed Labidi; Nouman Aldahak; Damien Bresson; Schahrazed Bouazza; Sebastien Froelich
Journal:  J Ophthalmic Vis Res       Date:  2018 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.